ZVRA Relative Valuation
ZVRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZVRA is overvalued; if below, it's undervalued.
Historical Valuation
Zevra Therapeutics Inc (ZVRA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -5.49. The fair price of Zevra Therapeutics Inc (ZVRA) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 8.66 USD , Zevra Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：8.66
Fair
Undervalued
18.50
PE
1Y
3Y
5Y
Trailing
Forward
12.56
EV/EBITDA
Zevra Therapeutics Inc. (ZVRA) has a current EV/EBITDA of 12.56. The 5-year average EV/EBITDA is -2.77. The thresholds are as follows: Strongly Undervalued below -53.46, Undervalued between -53.46 and -28.12, Fairly Valued between 22.58 and -28.12, Overvalued between 22.58 and 47.93, and Strongly Overvalued above 47.93. The current Forward EV/EBITDA of 12.56 falls within the Historic Trend Line -Fairly Valued range.
11.10
EV/EBIT
Zevra Therapeutics Inc. (ZVRA) has a current EV/EBIT of 11.10. The 5-year average EV/EBIT is 1313.73. The thresholds are as follows: Strongly Undervalued below -31379.03, Undervalued between -31379.03 and -15032.65, Fairly Valued between 17660.12 and -15032.65, Overvalued between 17660.12 and 34006.50, and Strongly Overvalued above 34006.50. The current Forward EV/EBIT of 11.10 falls within the Historic Trend Line -Fairly Valued range.
3.66
PS
Zevra Therapeutics Inc. (ZVRA) has a current PS of 3.66. The 5-year average PS is 9.57. The thresholds are as follows: Strongly Undervalued below -5.24, Undervalued between -5.24 and 2.17, Fairly Valued between 16.98 and 2.17, Overvalued between 16.98 and 24.39, and Strongly Overvalued above 24.39. The current Forward PS of 3.66 falls within the Historic Trend Line -Fairly Valued range.
11.18
P/OCF
Zevra Therapeutics Inc. (ZVRA) has a current P/OCF of 11.18. The 5-year average P/OCF is -2.76. The thresholds are as follows: Strongly Undervalued below -15.73, Undervalued between -15.73 and -9.25, Fairly Valued between 3.72 and -9.25, Overvalued between 3.72 and 10.21, and Strongly Overvalued above 10.21. The current Forward P/OCF of 11.18 falls within the Strongly Overvalued range.
12.30
P/FCF
Zevra Therapeutics Inc. (ZVRA) has a current P/FCF of 12.30. The 5-year average P/FCF is -2.45. The thresholds are as follows: Strongly Undervalued below -29.59, Undervalued between -29.59 and -16.02, Fairly Valued between 11.11 and -16.02, Overvalued between 11.11 and 24.68, and Strongly Overvalued above 24.68. The current Forward P/FCF of 12.30 falls within the Overvalued range.
Zevra Therapeutics Inc (ZVRA) has a current Price-to-Book (P/B) ratio of 3.66. Compared to its 3-year average P/B ratio of 5.14 , the current P/B ratio is approximately -28.93% higher. Relative to its 5-year average P/B ratio of 3.79, the current P/B ratio is about -3.63% higher. Zevra Therapeutics Inc (ZVRA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -13.45%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.95% , the current FCF yield is about -100.00% lower.
3.66
P/B
Median3y
5.14
Median5y
3.79
-4.94
FCF Yield
Median3y
-13.45
Median5y
-7.95
Competitors Valuation Multiple
The average P/S ratio for ZVRA's competitors is 27.80, providing a benchmark for relative valuation. Zevra Therapeutics Inc Corp (ZVRA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 605.36%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ZVRA increased by 3.84% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.70M to 26.06M.
The secondary factor is the Margin Expansion, contributed -99.77%to the performance.
Overall, the performance of ZVRA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Zevra Therapeutics Inc (ZVRA) currently overvalued or undervalued?
What is Zevra Therapeutics Inc (ZVRA) fair value?
How does ZVRA's valuation metrics compare to the industry average?
What is the current P/B ratio for Zevra Therapeutics Inc (ZVRA) as of Dec 05 2025?
What is the current FCF Yield for Zevra Therapeutics Inc (ZVRA) as of Dec 05 2025?
What is the current Forward P/E ratio for Zevra Therapeutics Inc (ZVRA) as of Dec 05 2025?